Table 4.
Randomized controlled trials assessing cardiovascular outcomes with thiazolidinediones
| Study | Completion | Population | Active | Comparator | Size | Primary Outcome | Point | Clinical Trials.gov registration |
|---|---|---|---|---|---|---|---|---|
| RECORD | Date Complete | T2DM, no recent cardiovascular events | Rosiglitazone | Placebo | 4447 | CV death/CV hospitalization, MI, CV death | Estimate 0.99 (0.85-act 1.16) | NCT00379769 |
| PROACTIVE | Complete | T2DM + evidence of macrovascular disease | Pioglitazone | Placebo | 5238 | T2DM1/macrovascular disease | 0.90 (0.80–1.02) | NCT00174993 |
| IRIS | Complete | Non-diabetic patients with recent ischemic stroke or TIA | Pioglitazone | Placebo | 3786 | Fatal or nonfatal stroke or MI | 0.76 (0.62–0.93) | NCT00091949 |
| TOSCA IT | 2018 | T2DM | Pioglitazone | Various sulfonylureas | 3371 | Composite of all cause mortality, nonfatal MI (including silent MI), nonfatal stroke, unplanned coronary revascularization | Anticipated 2018 | NCT00700856 |